About: The potential role of pneumococcal conjugate vaccine in reducing acute respiratory inflammation in community-acquired pneumococcal pneumonia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The potential role of pneumococcal conjugate vaccine in reducing acute respiratory inflammation in community-acquired pneumococcal pneumonia Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The potential role of pneumococcal conjugate vaccine in reducing acute respiratory inflammation in community-acquired pneumococcal pneumonia
Creator	Hsiung, Chao Huang, Yhu-Chering Huang, Li-Min Liu, Ching-Chuan Wang, Shih-Min Chi, Hsin Huang, Yi-Chuan Ho, Yu-Huai Lin, Hsiao-Chuan Pediatric, Taiwan Shen, Ching-Fen
topic	covid:50276e6a2e9c3e40745b214d955e3bdfefc46b13#this
Source	PMC
abstract	BACKGROUND: Pneumococcal conjugate vaccine (PCV) reduces both invasive pneumococcal disease (IPD) and other pneumococcal infections worldwide. We investigated the impact of stepwise implementation of childhood PCV programs on the prevalence of pneumococcal pneumonia, severity of acute inflammation, and associations between breakthrough pneumonia and pneumococcal serotypes in Taiwan. METHODS: In total, 983 children diagnosed with community-acquired pneumococcal pneumonia were enrolled between January 2010 and December 2015. RESULTS: Proportions of pneumococcal vaccinations increased each year in age-stratified groups with PCV7 (32.2%) as the majority, followed by PCV13 (12.2%). The proportion of pneumococcal pneumonia decreased each year in age-stratified groups, especially in 2–5 year group. Serotype 19A is the leading serotype either in vaccinated (6.4%) or unvaccinated patients (5.2%). In particular, vaccinated patients had significantly higher lowest WBC, lower neutrophils, lower lymphocytes and lower CRP values than non-vaccinated patients (p < 0.05). After stratifying patients by breakthrough infection, those with breakthrough pneumococcal infection with vaccine coverage serotypes had more severe pneumonia disease (p < 0.05). CONCLUSION: Systematic childhood pneumococcal vaccination reduced the prevalence of community-acquired pneumococcal pneumonia, especially in 2–5 year group. Serotype 19A was the major serotype for all vaccine types in patients with pneumococcal pneumonia and severity of acute inflammatory response was reduced in vaccinated patients.
has issue date	2020-08-19(xsd:dateTime)
bibo:doi	10.1186/s12929-020-00680-9
has license	cc-by
sha1sum (hex)	50276e6a2e9c3e40745b214d955e3bdfefc46b13
schema:url	https://doi.org/10.1186/s12929-020-00680-9
resource representing a document's title	The potential role of pneumococcal conjugate vaccine in reducing acute respiratory inflammation in community-acquired pneumococcal pneumonia
has PubMed Central identifier	PMC7435222
schema:publication	J Biomed Sci
resource representing a document's body	covid:50276e6a2e9c3e40745b214d955e3bdfefc46b13#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/50276e6a2e9c3e40745b214d955e3bdfefc46b13
is schema:about of	named entity 'pneumonia' named entity 'vaccinations' named entity 'pneumococcal pneumonia' named entity 'invasive pneumococcal disease' named entity 'coverage' named entity 'inflammation' named entity 'acquired' named entity '19A' named entity 'INVESTIGATED' named entity 'RESULTS' named entity 'CHILDREN' covid:arg/50276e6a2e9c3e40745b214d955e3bdfefc46b13 named entity 'PCV' named entity 'community-acquired' named entity 'patients' named entity 'serotypes' named entity 'impact' named entity 'serotype' named entity 'pneumococcal vaccination' named entity 'pneumococcal' named entity 'majority' named entity 'year group' named entity 'disease' named entity 'pneumococcal vaccinations' named entity 'lymphocytes' named entity 'acute inflammation' named entity 'serotypes' named entity 'pneumococcal pneumonia' named entity 'acute inflammatory response' named entity 'neutrophils' named entity 'severe pneumonia' named entity 'Taiwan' named entity 'PCV7' named entity 'vaccine' named entity 'pneumococcal pneumonia' named entity 'inflammation' named entity 'pneumococcal conjugate vaccine' named entity 'serotypes' named entity 'congenital heart disease' named entity 'vaccine' named entity '7.1' named entity 'invasive pneumococcal disease' named entity 'serotypes' named entity 'pneumococcal pneumonia' named entity 'pneumococcal pneumonia' named entity 'urine' named entity 'Linkou' named entity 'immune response' named entity 'PCV13' named entity 'acute inflammatory response' named entity 'pediatric' named entity 'Moraxella catarrhalis' named entity 'immunization' named entity 'pneumococcal pneumonia' named entity 'pneumococcal pneumonia' named entity 'mechanical ventilation' named entity 'vaccination' named entity 'bacteremia' named entity 'IPD' named entity 'Streptococcus pneumoniae' named entity 'pneumococcal pneumonia' named entity 'Taiwan' named entity 'vaccine' named entity 'mg/dl' named entity 'lungs' named entity 'significant impact' named entity 'pneumococcal pneumonia' named entity 'pneumococcal vaccine' named entity 'immunization' named entity 'pneumococcal pneumonia' named entity 'fulminant'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software